Skip to main content
Top
Literature
1.
go back to reference Oostdijk EA, Smits L, de Smet AM, Leverstein-van Hall MA, Kesecioglu J, Bonten MJ (2013) Colistin resistance in gram-negative bacteria during prophylactic topical colistin use in intensive care units. Intensive Care Med 39(4):653–660PubMedCrossRef Oostdijk EA, Smits L, de Smet AM, Leverstein-van Hall MA, Kesecioglu J, Bonten MJ (2013) Colistin resistance in gram-negative bacteria during prophylactic topical colistin use in intensive care units. Intensive Care Med 39(4):653–660PubMedCrossRef
3.
go back to reference Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268–281PubMedCrossRef Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268–281PubMedCrossRef
4.
go back to reference Nordmann P, Naas T, Poirel L (2011 Oct) Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17(10):1791–1798PubMedCrossRef Nordmann P, Naas T, Poirel L (2011 Oct) Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17(10):1791–1798PubMedCrossRef
5.
go back to reference Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, Bassetti M, Malacarne P, Petrosillo N, Galdieri N, Mocavero P, Corcione A, Viscoli C, Zarrilli R, Gallo C, Utili R (2013) Colistin and Rifampicin compared with Colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii. A multicentre, randomised, clinical trial. Clin Infect Dis. doi:10.1093/cid/cit253 PubMed Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, Bassetti M, Malacarne P, Petrosillo N, Galdieri N, Mocavero P, Corcione A, Viscoli C, Zarrilli R, Gallo C, Utili R (2013) Colistin and Rifampicin compared with Colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii. A multicentre, randomised, clinical trial. Clin Infect Dis. doi:10.​1093/​cid/​cit253 PubMed
Metadata
Title
Towards the end of the antibiotic era: let’s save the ancient soldier Colistin!
Authors
Alberto Corona
Riccardo Colombo
Publication date
01-09-2013
Publisher
Springer Berlin Heidelberg
Published in
Intensive Care Medicine / Issue 9/2013
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-013-2955-3

Other articles of this Issue 9/2013

Intensive Care Medicine 9/2013 Go to the issue